CIRRUS-2023-1: Evaluating PathFinder 1.0 for Macular Abnormalities

This study is testing a new software called PathFinder 1.0. This software analyzes images from a common eye scan called an OCT (Optical Coherence Tomography) to find problems in the macula (the central part of your retina responsible for sharp vision). We want to see how accurately PathFinder 1.0 can detect conditions like epiretinal membrane and dry age-related macular degeneration. You would have a standard OCT scan, and the software would analyze the images without changing your regular eye care. We are looking for about 400 adults, aged 18 and older, who are able to complete eye imaging and study visits. The study is currently unclear on its recruitment status.

Study design
This is an interventional study involving about 400 participants. It is designed to measure the sensitivity and specificity of PathFinder 1.0.
What's involved
You would need to attend required study visits and complete ophthalmic imaging. The primary endpoints are measured at a single study visit for OCT acquisition.
Compensation
Not stated in the trial record.
Follow-up
Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07680244

(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000

Recruiting
NAAges 18+InterventionalDiagnostic
Carl Zeiss Meditec-Dublin CoCe
~400 participants
Updated 2026-08-28 on ClinicalTrials.gov
What's tested:PathFinder 1.0 on CIRRUS HD-OCT

At a glance

Recruiting sites
5 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Sensitivity of PathFinder 1.0
Measured over Baseline (single study visit OCT acquisition)
+1 more outcome measured
Epiretinal Membrane
Dry Age Related Macular Degeneration
Macular Abnormalities
Retina Disease
Vitreoretinal Abnormality
Intraretinal Hyporeflective Space
Subretinal Hyporeflective Space
IS/OS (Ellipsoid Zone) Disruption
Retinal Pigment Epithelium (RPE) Elevation
Retinal Pigment Epithelium (RPE) Atrophy
6 sites across 5 states
California2
Arizona1
Florida1
Maine1
Missouri1

Opens a ready-to-send draft in your own email app — review before sending.

  • Sensitivity of PathFinder 1.0Baseline (single study visit OCT acquisition)

    Sensitivity is the proportion of scans that PathFinder 1.0 correctly identifies as having any macular abnormality.

  • Specificity of PathFinder 1.0Baseline (single study visit OCT acquisition)

    Specificity is the proportion of scans that PathFinder 1.0 correctly identifies as having no macular abnormality.